- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT01964976
Alogliptin Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Combination Therapy With Biguanides
Nesina Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Combination Therapy With Biguanides
Tutkimuksen yleiskatsaus
Tila
Ehdot
Yksityiskohtainen kuvaus
This is a special drug use surveillance on long-term use of alogliptin with a 1-year (12-month) observational period, designed to investigate the safety and efficacy of long-term combination therapy with alogliptin and biguanides in participants with type 2 diabetes mellitus in the routine clinical setting.
Participants diagnosed with type 2 diabetes mellitus who responded inadequately to treatment with biguanides in addition to diet therapy and exercise therapy will be enrolled. The planned sample size is 1,000.
The usual adult dosage for oral use is 1 alogliptin tablet (25 mg) once daily.
Opintotyyppi
Ilmoittautuminen (Todellinen)
Yhteystiedot ja paikat
Opiskelupaikat
-
-
-
Tokyo, Japani
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
- Lapsi
- Aikuinen
- Vanhempi Aikuinen
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Näytteenottomenetelmä
Tutkimusväestö
Kuvaus
Inclusion Criteria:
- Participants who did not adequately respond to the following treatment • Treatment with biguanides in addition to diet therapy and exercise therapy
Exclusion Criteria:
Participants contraindicated for Nesina
- Participants with severe ketosis, diabetic coma or precoma, or type 1 diabetes mellitus [these participants require prompt adjustment of hyperglycemia by fluid infusion and insulin, and hence use of Nesina is not appropriate].
- Participants with severe infection, pre- or post-operative patients, or patients with serious traumatic injury [blood glucose control by insulin injection is desirable for these participants, and hence use of Nesina is not appropriate].
- Participants with a history of hypersensitivity to any ingredient of Nesina.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
Kohortit ja interventiot
Ryhmä/Kohortti |
---|
Alogliptin + Biguanides
All participants who received alogliptin 25 milligram (mg), tablets, orally, once daily for up to 12 months along with biguanide or without biguanide within 3 months from the start of administration of alogliptin and during the treatment period of alogliptin as per routine clinical practice were observed in this study.
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Number of Participants Reporting One or More Adverse Drug Reactions
Aikaikkuna: Baseline up to 12 months
|
Adverse drug reactions are defined as adverse events (AEs) which are in the investigator's opinion of causal relationship to the study treatment.
AEs are defined as any unfavorable and unintended signs, symptoms or diseases temporally associated with the use of a medicinal product reported from the first dose of study drug to the last dose of study drug.
The safety analysis was planned to be assessed in alogliptin + biguanides and alogliptin + other arm separately.
|
Baseline up to 12 months
|
Number of Participants Reporting One or More Serious Adverse Drug Reactions
Aikaikkuna: Baseline up to 12 months
|
Serious adverse drug reactions are defined as serious adverse events (SAEs) which are in the investigator's opinion of causal relationship to the study treatment.
An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
The safety analysis was planned to be assessed in alogliptin + biguanides and alogliptin + other arm separately.
|
Baseline up to 12 months
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Change From Baseline in Glycosylated Hemoglobin (HbA1c)
Aikaikkuna: Baseline, Months 1, 3, 6, 12, and final assessment (up to Month 12)
|
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at 1 month, 3 months, 6 months, 12 months or final visit (last visit for a participant in the study, up to Month 12) relative to baseline.
The efficacy analysis was planned to be assessed in the total alogliptin arm irrespective of biguanide treatment.
|
Baseline, Months 1, 3, 6, 12, and final assessment (up to Month 12)
|
Percentage of Participants of Achieving Objective Glycemic Control
Aikaikkuna: Baseline and final assessment (up to Month 12)
|
The rate of achieving objective glycemic control in HbA1c level, was calculated at 12 month or final visit (last visit for a participant in the study, up to Month 12).
Glycemic control was measured as <8.0%, <7.0%, and <6.0% of glycosylated hemoglobin.
The efficacy analysis was planned to be assessed in the total alogliptin arm irrespective of biguanide treatment.
|
Baseline and final assessment (up to Month 12)
|
Change From Baseline in Fasting Blood Glucose
Aikaikkuna: Baseline, Months 1, 3, 6, 12, and final assessment (up to Month 12)
|
The change between the fasting blood glucose value collected at 1 month, 3 months, 6 months, 12 months or final visit (last visit for a participant in the study, up to Month 12) relative to baseline.
The efficacy analysis was planned to be assessed in the total alogliptin arm irrespective of the biguanide treatment.
|
Baseline, Months 1, 3, 6, 12, and final assessment (up to Month 12)
|
Change From Baseline in Fasting Insulin Level
Aikaikkuna: Baseline, Months 1, 3, 6, 12, and final assessment (up to Month 12)
|
The change between the fasting insulin value collected at 1 month, 3 months, 6 months, 12 months or final visit (last visit for a participant in the study, up to Month 12) relative to baseline.
The efficacy analysis was planned to be assessed in the total alogliptin arm irrespective of biguanide treatment.
|
Baseline, Months 1, 3, 6, 12, and final assessment (up to Month 12)
|
Yhteistyökumppanit ja tutkijat
Sponsori
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Arvio)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- 121-014
- JapicCTI-132282 (Rekisterin tunniste: JapicCTI)
- JapicCTI-R150790 (Rekisterin tunniste: JapicCTI)
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .